Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Kerecis logo — Kerecis is pioneering the use of fish skin and fatty-acids i...

Kerecis

Kerecis is pioneering the use of fish skin and fatty-acids in the cellular therapy and regenerative medicine market.

Founded 2011 Iceland Iceland 517 employees Debt Financing Total: $210.77M Health Care, Manufacturing +1

General Information

Company Name Kerecis
Founded Year 2011
Location Iceland Iceland +4
Founders / Decision Makers
Team member Team member Team member Team member Team member Team member
Employees 517
Industries Health Care, Manufacturing, Medical Devices
Funding Stage Debt Financing
Social

Get notified when Kerecis moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Kerecis

Kerecis is a pioneering company in the cellular therapy and regenerative medicine market, using fish skin and fatty acids to revolutionize tissue healing. Founded in 2009 by Fertram Sigurjonsson, the company's patented technologies leverage fatty-acid rich products to enable tissue regeneration, minimizing scarring. Their products are utilized in treating trauma, chronic wounds, burns, and diabetic wounds, with future applications in oral surgery, plastic surgery, and neurological treatments. Kerecis is driven by a vision to extend human life by supporting the body’s own regenerative abilities and a mission to lead the world in regenerative medicine while sustainably harnessing nature’s remedies. A significant milestone for Kerecis was reached in August 2023 when it achieved unicorn status, becoming Iceland’s first unicorn with a groundbreaking acquisition by the Danish company Coloplast for an impressive $1.3 Billion. This achievement solidifies the company's position as a leader in the industry. In its most recent funding round, Kerecis secured a $60.00M Series D investment on 21 July 2022, with notable investors including Emerson Collective, KIRKBI, Brú Pension Fund, and LSV. Kerecis has carved out a unique position in the Health Care and Manufacturing sectors, driving innovation from its headquarters in Iceland. With its groundbreaking technology and strong investor backing, Kerecis is poised to continue its trajectory of success and influence in the regenerative medicine market.

Taxonomy: Regenerative Medicine, Cellular Therapy, Wound Care, Burn Treatment, Surgical Procedures, Dental Applications, Omega-3, Fish-skin Technology, Tissue Regeneration, Startup, Investment, Healthcare Innovation, Biomedical Research

Funding Rounds & Investors (19)

View All
Funding Stage Amount Investors Lead Investors Date
Debt Financing •••••• 1 •••• •••• 21 Jul 2022
Series D •••••• 4
Investor Investor
•••• •••• 		21 Jul 2022
Convertible Note •••••• 1 •••• •••• 27 Aug 2020
Series C •••••• 4
Investor
•••• •••• 		13 Jun 2019
Convertible Note •••••• - 07 Jan 2018

View All 19 Funding Rounds

Latest News

View All
Iceland’s first unicorn will spur investment but don’t expect “floodgates” to open, says unicorn fou... — Tech
Iceland’s first unicorn will spur investment but don’t expect “floodgates” to open, says unicorn founder
Tech May 24, 2024

Kerecis Alternatives & Competitors

Kerecis vs
BioSyntech
BioSyntech

BioSyntech is a medical device company specialized in the development, manufacturing and commerciali...

Series Unknown
16 employees
Biotechnology, Health Care
Compare Kerecis vs BioSyntech
Kerecis vs
Stratatech Corporation
Stratatech Corporation

Stratatech Corporation, a leader in regenerative medicine, focuses on the development and commercial...

Grant
Biotechnology, Pharmaceutical
Compare Kerecis vs Stratatech Corporation
Kerecis vs
HansBiomed Corp.
HansBiomed Corp. Korea South

Experience real-time webinar, various medical information services provided by HANS FACULTY NOW.

49 employees
Health Care, Medical Devices
Compare Kerecis vs HansBiomed Corp.

FAQ About Kerecis

Kerecis is pioneering the use of fish skin and fatty-acids in the cellular therapy and regenerative medicine market.
Kerecis was founded in 2011.
Kerecis is headquartered in Iceland.
Kerecis operates in the following industries: Health Care, Manufacturing, Medical Devices.
Kerecis has approximately 517 employees.
Kerecis has completed 19 funding rounds, raising a total of $210.77M. The latest funding stage is Debt Financing.
Top alternatives and competitors to Kerecis include BioSyntech, Stratatech Corporation, HansBiomed Corp., Ivivi Technologies, Rapid Nexus Nanotech Wound Solutions, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Kerecis and BioSyntech are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Kerecis and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy